Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Effect of metoprolol on activity of β-adrenoceptor coupled to guanine nucleotide binding regulatory proteins in adriamycin-induced cardiotoxicity

  • 43 Accesses

  • 27 Citations

Summary

Prevention of cardiotoxicity without interfering with the therapeutic efficacy of adriamycin is a very crucial question. We have investigated the activity of β-adrenoceptor coupled to guanine nucleotide binding regulatory proteins (G-proteins) and Ca2+-ATPase activity in experimental adriamycin-induced cardiotoxicity and the influence of metoprolol treatment on these variables. Adriamycin was administered to rats intravenously as a single dose of 6 mg/kg, and metoprolol was continuously given by means of implanted osmotic pumps. β-adrenoceptor characteristics were measured by radioligand-binding experiments and by basal and stimulated adenylyl cyclase activity. Northern blot and dot blot analysis was used to quantify G-protein mRNA. It was shown that adriamycin did not induce any change in the total β-adrenoceptor density, nor did the high affinity agonist binding to β-adrenoceptor change. Adriamycin did not induce any alteration in the amount of mRNA encoding for stimulatory (Gs) or inhibitory (Gi) G-proteins. Also, basal and stimulated adenylyl cyclase activities were identical in the different experimental groups. In contrast, the Ca2+-ATPase was shown to increase in adriamycin-treated rats compared to control rats (45 ± 3.8 versus 23 ± 1.2 μmol Pi/mg/h, P < .01). Metoprolol was shown to normalize this increase (29 ± 2.1 μmol Pi/mg/h). Thus, it may be concluded that in experimental adriamycin-induced cardiotoxicity, despite Ca2+-overloading, the β-adrenoceptor-G protein-adenylyl cyclase system remains intact. Metoprolol seems to prevent Ca2+-overloading independently of the β-adrenoceptors studied here.

This is a preview of subscription content, log in to check access.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

References

  1. 1.

    Bast A, Kramer K, Leurs R, Timmerman H (1986) Decrease in beta-adrenoceptor density during lipid peroxidation. Brit J Pharmacol 89, Suppl:695P

  2. 2.

    Bristow MR, Mason JW, Billingham ME, Daniels JR (1978) Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Int Med 88:168–175

  3. 3.

    Bristow MR, Ginsburg R, Strosberg A, Montgomery W, Minobe W (1984) Pharmacology and inotropic potential of forskolin in the human heart. J Clin Invest 74:213–223

  4. 4.

    Bristow MR, Ginsburg R, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Stinson E (1986) Beta 1- and beta 2-adrenergic receptor subpopulations in normal and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1 receptor down regulation in heart failure. Circ Res 59:297–308

  5. 5.

    Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM (1990) Beta-adrenoceptor pathways in non-failing and failing human ventricular myocardium. Circulation 82, Suppl 1:1-12–1-25

  6. 6.

    Brown AM, Birnbaumer L (1988) Direct G protein gating of ion channels. Am J Physiol 254:H401–410

  7. 7.

    Caulfield JB, Bittner V (1988) Cardiac matrix alterations induced by adriamycin. Am J Pathol 133:298–305

  8. 8.

    Chirgwin JJ, Przbyla AE, MacDonald RJ, Rutter WJ (1979) Isolation of biologically active ribonucleic acid from source enriched in ribonuclease. Biochem 18:5294–5299

  9. 9.

    Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, Strosberg AD (1989) Molecular characterization of the human beta 3-adrenoceptor. Science 245:1118–1121

  10. 10.

    Feinberg AP, Vogelstein B (1984) A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Addendum. Anal Biochem 137:266–267

  11. 11.

    Feldman AM, Cates AE, Bristow MR, Van Dop C (1989) Altered expression of alpha subunits of G proteins in failing human hearts. J Mol Cell Cardiol 21:359–365

  12. 12.

    Fu LX, Waagstein F, Hjalmarson Å (1990) A new insight into adriamycin-induced cardiotoxicity. Intern J Cardiol 29:15–20

  13. 13.

    Golf S, Hansson V (1986) Effects of beta blocking agents on the density of beta-adrenoceptors and adenylyl cyclase response in human myocardium: Intrinsic sympathomimetic activity favours receptors upregulation. Cardiovascular Res 20:637–644

  14. 14.

    Gwathmey JK, Copelas L, Mackinnon, Schoen FJ, Feldman MD, Grossman W, Morgan JP (1987) Abnormal intracellular calcium handling in myocardium from patients with end stage heart failure. Circ Res 61:70–76

  15. 15.

    Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB (1989) Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circ 79:483–490

  16. 16.

    Ikonomidis JS, Salerno TA, Wittnich C (1990) Calcium and the heart: an essential partnership. Can J Cardiol 6:305–316

  17. 17.

    Jones DT, Reed RR (1987) Molecular cloning of five GTP-binding protein cDNA species from rat olfactory neuroepithelium. J Biol Chem 262(29):14241–14249

  18. 18.

    Kaneko M, Singal PK, Dhalla NS (1990) Alterations in heart sarcolemmal Ca2+-ATPase and Ca2+-binding activities due to oxygen free radicals. Basic Res Cardiol 85(1):45–54

  19. 19.

    Karliner JS (1989) Effects of beta-blockade on beta-adrenergic receptor and signal transduction. J Cardiovascular Pharmacol 14, Suppl 5:S6–S12

  20. 20.

    Kaumann AJ (1989) Is there a third heart beta-adrenoceptor. Trend Pharmacol Sci 10:316–320

  21. 21.

    Limas CJ, Olivari MT, Goldenberg IF, Levine TB, Benditt DG, Simon A (1987) Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovas Res 21:601–605

  22. 22.

    Linzbach AJ (1960) Heart failure from the point of view of quantitative anatomy. Am J Cardiol 5:370–382

  23. 23.

    Lowry DH, Rosebrough NJ, Fan AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275

  24. 24.

    Makino N, Dhalla KS, Elimban V, Dhalla NS (1987) Sarcolemmal Ca2+-transport in streptozotocin induced diabetic cardiomyopathy in rats. Am J Physiol E 202–207

  25. 25.

    Morgan JP, Erny RE, Allen PD, Grossman W, Gwathmey JK (1990) Abnormal intracellular calcium handling a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation 81, Suppl III:III-12–III-32

  26. 26.

    Panagia V, Lames JMJ, Singal PK, Dhalla NS (1982) Ca2+- and Mg2+-dependent ATPase activities in the deoxycholate-treated rat heart sarcolemma. Int J Biochem 14:387–397

  27. 27.

    Rasmussen IMN, Schoi HS, Hermansen K (1989) Cardiotoxic effects and the influence on the betaadrenoceptor function of doxorubicin (adriamycin) in the rat. Pharm Toxicol 65:69–72

  28. 28.

    Robison TW, Giri SN (1986) Effect of chronic administration of doxorubicin on myocardial betaadrenoceptors. Life Sci 39:731–736

  29. 29.

    Salomon Y, Londos C, Rodbell M (1974) A highly sensitive adenylate cyclase assay. Anal Biochem 58:541–548

  30. 30.

    Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51:660–672

  31. 31.

    Singal PK, Deally CMR, Weinberg LE (1987) Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 19:817–828

  32. 32.

    Solcia E, Ballerina L, Bellini O, Magrini V, Bertazzoli C, Tosana G, Sala L, Balconi F, Rallo F (1981) Cardiomyopathy of doxorubicin in experimental animals: Factors affecting the severity, distribution and evolution of myocardial lesions. Tumori 67:461–472

  33. 33.

    Stiles GL, Caron MG, Lefkowitz RJ (1984) Beta-adrenergic receptor: Biochemical mechanisms of physiological regulation. Physiol Rev 64(2):661–743

  34. 34.

    Taussky HH, Shorr E (1953) A microcolorimetric method for the determination of inorganic phosphate. J Biol Chem 202:675–685

  35. 35.

    Waagstein F, Caidahl K, Wallentin I, Bergh C-H, Hjalmarson A (1989) Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metroprolol. Circulation 80:551–563

  36. 36.

    Waagstein F (1990) Beta-blockade in dilated cardiomyopathy. In: Baroldi G, Camerini F, Goodwin JF (eds) Advance in cardiomyopathies. Springer-Verlag, Berlin Heidelberg New York, pp 435–447

  37. 37.

    Woodcock EA, Arnolda L, McGrath BP (1988) Ventricular beta-adrenoceptors in adriamycininduced cardiomyopathy in the rabbit. J Mol Cell Cardiol 20:771–777

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fu, L.X., Bergh, C., Hoebeke, J. et al. Effect of metoprolol on activity of β-adrenoceptor coupled to guanine nucleotide binding regulatory proteins in adriamycin-induced cardiotoxicity. Basic Res Cardiol 86, 117–126 (1991). https://doi.org/10.1007/BF02190544

Download citation

Key words

  • Metoprolol
  • adriamycin
  • G-proteins
  • β-adrenoceptor
  • adenylyl cyclaseCa2+-ATPase
  • myocardium